Pathological Interaction Mechanisms between Cervical Mycoplasma and Chlamydia Infections and Endometriosis: Novel Clinical Management Strategies

Endometriosis (EMs), a prevalent chronic inflammatory disease among women of reproductive age, has a global prevalence of 10% - 15% and is closely asso- ciated with 30% - 50% of infertility cases. This review systematically examines the epidemiological characteristics and molecular pathogenesis of EMs, estab- lishing for the first time a dynamic interaction model between cervical myco- plasma and chlamydia infections in the pat hological progression of EMs. Based on epidemiological correlation analysis, it reveals the spatiotemporal association between genital tract infections and EMs onset. By examining in- flammatory pathway interactions, immune dysregulation, and microbiome imbalance, it elucidates the potential infection -inflammation-endometriosis “pathological vicious cycle”. Clinically, it innovatively proposes a “dual-track treatment” strategy integrating targeted hormone therapy, precision anti -in- fective regimens, and combined immune -microbiome modulation. This re- view constructs a precision prevention and treatment system through a trans- lational medicine perspective. It not only achieves a paradigm shift in diagno- sis and treatment from “symptom control” to “etiological intervention” but also provides EM patients with personalized treatment pathways based on mo- lecular subtyping. This breakthrough offers a novel methodological frame- work for addressing treatment resistance and recurrence prevention in EM.

Endometriosis (EMs), Immune Dysregulation, Chronic Inflammation, Mycoplasma and Chlamydia Infections *Corresponding author. How to cite this paper: Wei, Z.D. and Yi, C.J. (2025) Pathological Interaction Mecha- nisms between Cervical Mycoplasma and Chlamydia Infections and Endometriosis: Novel Clinical Management Strategies. Journal of Biosciences and Medicines, 13, 209-225. https://doi.org/10.4236/jbm.2025.1311015 Received: October 11, 2025 Accepted: November 8, 2025 Published: November 11, 2025 Copyright © 2025 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 210 Journal of Biosciences and Medicines 1. Introduction Endometriosis is a common chronic gynecological disorder among women of re- productive age. Clinically, it manifests as the growth of endometrioid tissue out- side the uterine cavity, primarily distributed within the pelvic cavity — including the ovaries, fallopian tubes, peritoneum, and bladder surface. Its global prevalence is approximately 10%, rising to 30% - 50% among women with infertility [1]. Symptoms of endometriosis exhibit high heterogeneity, including chronic pelvic pain, menstrual irregularities, infertility, and dyspareunia. These symptoms sig- nificantly impact patients ’ quality of life and mental health [2]. The etiology of endometriosis is complex, and its pathogenesis remains incompletely understood. Current mainstream theories include retrograde menstruation, immune dysregu- lation, genetic susceptibility, and stem cell mechanisms. Retrograde menstruation is considered the primary source of ectopic endometrial implantation, yet not all women develop endometriosis , suggesting other factors — such as immune dys- function and inflammatory responses— play crucial roles in disease onset and pro- gression [3]. Concurrently, Mycoplasma and Chlamydia infections of the cervix, as the most prevalent sexually transmitted infections in the female reproductive tract, impact reproductive health through their chronic and insidious nature. These pathogens not only cause chronic pelvic inflammation but are also fre- quently associated with reproductive disorders, such as tubal obstruction, infer- tility, and recurrent miscarriage. In recent years, increasing research has focused on the potential interplay between Mycoplasma and Chlamydia infections and endometriosis, particularly at the level of shared inflammatory a nd immunoreg- ulatory mechanisms. While Ureaplasma urealyticum and Chlamydia trachomatis infections are pre- dominantly associated with pelvic inflammatory disease and reproductive disor- ders, their direct link to endometriosis remains incompletely understood. Some studies suggest these pathogens may interact with endometriosis through shared inflammatory pathways. For instance, Ureaplasma infection significantly upregu- lates TNF- α and IL-1β expression— inflammatory mediators also demonstrated to be markedly elevated in endometriosis [4]. Similarly, Chlamydia trachomatis infection may influence the formation and progression of endometriosis by dis- rupting mucosal barriers, activating the innate immune system, and promoting inflammatory responses and tissue fibrosis [5]. This review will therefore examine the epidemiological characteristics, potential associative mechanisms, and current clinical interventions regarding endometriosis and cervical Mycoplasma/Chla- mydia infections, while also outlining future research directions and clinical man- agement strategies. 2. Endometriosis 2.1. Pathogenesis of Endometriosis The early classical theory, the Retrograde Menstruation Theory, posits that during menstruation, fragments of endometrial tissue flow retrograde through the fallo- Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 211 Journal of Biosciences and Medicines pian tubes into the pelvic cavity, implanting at ectopic sites to form lesions. This theory provides a crucial foundation for explaining the origin of ectopic endome- trial tissue. However, retrograde menstruation is also common in healthy women, suggesting that retrograde flow alone is insufficient to induce endometriosis. Con- sequently, researchers further explored that abnormalities in host immune func- tion may be crucial for the implantation and survival of ectopic endometrial tis- sue. In patients with endometriosis, natural killer (NK) cell activity is significantly reduced, and macrophage clearance function is weakened. This impairs the timely removal of endometrial tissue entering the pelvic cavity, allowing it to survive and form ectopic lesions. Furthermore, ectopic endometrial tissue itself secretes large amounts of pro-inflammatory cytokines (such as IL-1 β, TNF-α, IL-6, etc.). These factors further activate local pelvic inflammatory responses and immune system dysregulation, creating an “inflammation -immune abnormality” environment that ultimately promotes disease progression. Endometriosis exhibits distinct hormone -dependent characteristics. Research indicates that the root cause of significantly elevated estrogen levels within ectopic lesions lies in the abnormally high expression of aromatase (CYP19A1). As the key enzyme conv erting androgens to estrogens, aromatase becomes hyperactive at lesion sites, continuously converting androgens into estrogens. This creates a localized “high estrogen environment,” stimulating persistent growth and prolif- eration of ectopic endometrial tis sue, thereby driving disease progression. Con- currently, ectopic endometrial tissue exhibits resistance to progesterone, known as progesterone resistance. Under normal circumstances, progesterone effectively suppresses endometrial cell proliferation and maintains endometrial homeostasis. However, in this disease, endometrial tissue responds poorly to progesterone, di- minishing its antiproliferative capacity and preventing effective control of ectopic endometrial proliferation. The negative effects of estrogen extend beyond pro- moting endometrial growth. It also activates inflammatory pathways such as the NF- κB pathway, further stimulating local inflammatory responses. This exacer- bates tissue damage and immune imbalance, driving disease progression. Genetic studies indicate familial clustering in endometriosis. Genome-wide as- sociation studies (GWAS) have identified multiple disease-associated genetic loci, including WNT4, VEZT, GREB1, and FN1. These genes play crucial roles in reg- ulating endometrial t issue adhesion, migration, and invasiveness. For instance, VEZT gene overexpression enhances ectopic tissue adhesion to surrounding stroma, while GREB1 abnormalities likely accelerate disease progression by disrupting es- trogen signaling pathways. Endometriotic lesions exhibit tumor-like characteris- tics, primarily manifested as abnormal, increased angiogenesis, and enhanced in- vasiveness. High expression of matrix metalloproteinases (MMP -2 and MMP-9) within lesions promotes degradation of the basement membrane and extracellular matrix, enhancing the migration and invasiveness of ectopic tissue. Concurrently, elevated vascular endothelial growth factor (VEGF) levels in ectopic tissues stim- ulate neovascularization, supplying essential blood flow and nutrients to sustain Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 212 Journal of Biosciences and Medicines lesion survival. This perpetuates ectopic foci, complicating therapeutic manage- ment. 2.2. Local Effects of Chronic Inflammation A prominent pathological feature of endometriosis lies in the ability of ectopic lesions to secrete multiple inflammatory mediators, thereby establishing a persis- tent chronic inflammatory state within the pelvis. Research indicates that ectopic endometrial tissue secretes pro-inflammatory factors such as IL-1, IL-6, and TNF- α. These mediators not only activate macrophages and neutrophils in the pelvis, creating a stable pro -inflammatory environment, but also disrupt normal tissue structures, leading to issues like tubal obstruction and local fibrosis [6]-[8]. Pro- longed inflammatory stimulation promotes excessive collagen deposition, trigger- ing fibrosis in the lesions and surrounding tissues. This not only impairs repro- ductive organ function but also makes complete surgical removal of the lesions difficult [6]. Furthermore, nerve growth factor (NGF) secreted by ectopic lesions can induce local neurosensitization and abnormal neurogenic connections, fur- ther exacerbating the patient’s chronic pain state. More notably, persistent chronic pelvic inflammation may compromise the lo- cal mucosal barrier and induce immune dysregulation, thereby increasing cervical susceptibility to pathogens. Research indicates that under chronic inflammatory conditions, excessive release of pro-inflammatory mediators and immune imbal- ance create favorable conditions for Mycoplasma and Chlamydia adhesion and invasion, forming an “infection-inflammation-ectopic” cycle that may exacerbate endometriosis progression [9] [10]. 2.3. Microbiome Dysbiosis and Endometriosis In recent years, the potential impact of the reproductive tract microbiome on en- dometriosis has garnered increasing attention. Studies reveal significantly reduced Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 213 Journal of Biosciences and Medicines microbial diversity in the reproductive tract of endometriosis patients, character- ized by decreased dominant bacteria (e.g., lactobacilli) and increased proportions of opportunistic pathogens (e.g., Ureaplasma urealyticum and Chlamydia tracho- matis) [11]. These microbial alterations may influence disease through multiple mechanisms: Ureaplasma and Chlamydia infections can induce massive pro -in- flammatory factor secretion, activating inflammatory mediators that directly or indirectly exacerbate endometriotic lesions [12]. Additionally, dysbiosis may com- promise mucosal barrier function, impairing the immune system’s ability to clear ectopic endometrial tissue. 3. Characteristics of Mycoplasma and Chlamydia Infections 3.1. Characteristics of Cervical Mycoplasma and Chlamydia Infections and Their Relationship with Reproductive System Diseases Cervical Mycoplasma and Chlamydia infections are the most common sexually transmitted infections (STIs) in the female reproductive system, with Ureaplasma urealyticum and Chlamydia trachomatis being the primary pathogens. Ureaplasma urealyticum is a small pathogen lacking a cell wall. Under specific conditions, such as immunosuppression or microecological imbalance, it can trans- form into a pathogenic bacterium. Characteristics of Ureaplasma urealyticum in- fection include high infection rates and stealthiness. Studies indicate that Ureaplasma urealyticum carriage rates among sexually active women reach 40% - 80%, though most infected individuals exhibit no apparent symptoms [11] [12]. Prolonged chronic infection may lead to pelvic inflammatory disease, salpingitis, infertility, and pregnancy complications [13]. Notably, Ureaplasma urealyticum induces lo- cal immune dysregulation and tissue damage by adhering to epithelial cells and secreting toxic factors and inflammatory mediators. This chronic inflammatory environment within the pelvis may interact with the development and progression of endometriosis: on one hand, persistent inflammation and immune abnormali- ties provide a “fertile ground” for ectopic endometrial tissue to adhere, grow, and undergo angiogenesis; On the other hand, the preexisting inflammatory back- ground or dysbiosis in endometriosis patients may further increase susceptibility to Ureaplasma infection, thereby forming an “infection -inflammation-endome- triosis” cycle. Chlamydia trachomatis is another common genital tract pathogen. Chlamydia infections are typically asymptomatic, potentially leading to missed treatment windows and progression to chronic pelvic inflammatory disease, tubal obstruc- tion, infertility, and ectopic pregnancy [14]. Chlamydia trachomatis survives and replicates within host cells through conversion between the reticulate and primary forms, evading immune recognition while releasing inflammatory mediators that disrupt the genital tract mucosal barrier [15]. Research indicates that Chlamydia trachomatis infection may trigger systemic immune responses, further impairing reproductive function [16]. Therefore, in-depth investigation of the bidirectional Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 214 Journal of Biosciences and Medicines effects of these pathogens on the reproductive tract microenvironment, immune mechanisms, and endometriotic lesions holds significant importance for main- taining female reproductive health. 3.2. How Anatomical and Physiological Characteristics Make the Cervix a Primary Site for Mycoplasma and Chlamydia Infections The cervix is a high- risk site for infections in the female reproductive tract, with its unique anatomical and physiological characteristics determining its high sus- ceptibility to pathogens. Located at the junction of the lower and upper reproduc- tive tracts, the cervix possesses a complex anatomical structure and mucosal bar- rier function, playing a vital role in maintaining reproductive tract health and pre- venting pathogen invasion. However, under certain specific conditions, these bar- rier functions may be compromised, thereby increasing the risk of infection. The mucus secreted by cervical glands forms a vital barrier against ascending infections. Its viscosity and composition undergo dynamic changes throughout the menstrual cycle under hormonal influence [17]. During ovulation, the mucus thins to facilitate sperm passage; by the luteal phase, it thickens to enhance de- fense. However, pathogens like Ureaplasma urealyticum can compromise barrier function by secreting enzymes that degrade mucus components or reducing anti- microbial peptides (e.g., defensins, lysozyme) within it [18]. The squamo-columnar junction of the cervix represents a transitional zone be- tween squamous and columnar epithelium. Here, newly generated cells exhibit high activity but an immature barrier, with loose intercellular connections that facilitate pathogen adhesion and invasion [19]. Chlamydia trachomatis and Ureaplasma urea- lyticum bind to epithelial cells via surface adhesion proteins, achieving coloniza- tion and replication in this region [20]. Chronic inflammation further damages local epithelium, increasing genetic mutation risk and elevating susceptibility to other cervical pathologies. These dual characteristics render the cervix highly sus- ceptible to pathogens like mycoplasma and chlamydia. Any factor weakening the mucus barrier or altering local epithelial structure— such as hormonal imbalances or microbiome disruption— may heighten infection risk and foster persistent in- flammation within the pelvic cavity. The cervical microenvironment provides multiple conditions conducive to pathogen growth and reproduction. Under normal circumstances, the cervical microecology maintains an optimal acidic pH (approximately 4.0) through the metabolic activity of lactobacilli, thereby inhibiting the growth of most pathogens [21]. However, when microecological imbalance occurs (e.g., reduced lactobacilli or increased proportion of opportunistic pathogens), local pH may rise, compro- mising the natural anti-infective barrier. For instance, excessive antibiotic use or poor hygiene practices may disrupt the vaginal microbiota, creating favorable con- ditions for Chlamydia trachomatis and Ureaplasma urealyticum proliferation. Ad- ditionally, the humidity and temperature conditions within cervical tissue support the survival and transmission of these pathogens [22]. Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 215 Journal of Biosciences and Medicines Beyond anatomical and microenvironmental factors, the cervical mucosa’s lo- cal immune characteristics also contribute to its susceptibility. Although the cer- vical mucosa harbors diverse immune cells (e.g., macrophages and T cells) and antibodies (e.g., IgA) capable of defending against pathogens, certain pathogens possess immune evasion mechanisms. For instance, Chlamydia trachomatis sup- presses host autophagy to evade immune clearance [23]. Ureaplasma urealyticum can weaken the host immune response by mutating surface antigens, thereby es- tablishing persistent infection. The anatomical and physiological characteristics of the cervix determine its role as a primary site for Mycoplasma and Chlamydia infections. These include its clean structure and the dynamics of its microenvironment [24]. Pathogens achieve invasion and replication by disrupting the mucus barrier, adhering to susceptible areas, altering the local environment, or evading the immune system. These char- acteristics not only form a crucial basis for infection but also suggest that strength- ening barrier protection and regulating the microenvironment in the cervical re- gion are vital for preventing related infections. 3.3. Pathogenesis of Mycoplasma and Chlamydia Infections Mycoplasma and Chlamydia infections represent the most prevalent pathogenic infections in the female reproductive system, with complex pathogenesis involv- ing multiple pathways and pathological changes. These pathogens colonize hosts through mechanisms including adhesion, invasion, and immune evasion, trigger- ing local and systemic inflammatory responses. They may induce chronic patho- logical damage, ultimately impairing reproductive function.[25]. Ureaplasma urealyticum, a cell wall-deficient microorganism, relies on surface adhesion proteins to bind to host cells, enabling attachment and colonization on the surface of cervical epithelial cells. Its unique adhesion mechanism allows it to firmly attach to susceptible sites such as the squamocolumnar junction of the cer- vix, laying the groundwork for subsequent infection [24]. Furthermore, Ureaplasma releases toxic substances during metabolism, such as urease and peroxides. These products not only directly damage host cell membranes but also exacerbate local in- flammatory responses by inducing oxidative stress [26]. Simultaneously, Ureaplasma activates the host immune system, significantly upregulating the expression of pro-inflammatory factors like IL -6 and TNF - α, attracting large numbers of im- mune cells to the infection site. This excessive immune response, while eliminat- ing pathogens, also causes irreversible tissue damage. Particularly, its immune evasion capabilities— such as antigenic variation and suppression of complement activation— enable it to evade immune surveillance long -term, leading to persis- tent infection and chronic inflammation. Chlamydia trachomatis achieves infection and proliferation through its unique life cycle [27]. Its elementary body (EB) adheres to host cell surfaces and enters cells via phagocytosis, transforming into a reticular body (RB) intracellularly. It rapidly replicates and forms inclusion bodies. This process not only disrupts host Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 216 Journal of Biosciences and Medicines cell structures but also expands infection by releasing inflammatory mediators. The NF-κB signaling pathway activated during Chlamydia trachomatis infection significantly increases the secretion of pro-inflammatory cytokines such as IL-1β, IL-8, and IFN-γ. These factors sustain local inflammation through a self-amplify- ing mechanism [28]. Furthermore, Chlamydia trachomatis exhibits potent immune evasion capabilities, such as suppressing host antigen presentation by downregulat- ing MHC-I and MHC-II molecule expression, or evading clearance by interfering with host autophagy pathways. These mechanisms collectively contribute to the persistence and refractory nature of its infection [29]. 3.4. The Relationship Between Mycoplasma and Chlamydia Infections and Chronic Inflammation Whether caused by Mycoplasma or Chlamydia infections, the common patho- logical feature is tissue damage and functional abnormalities triggered by chronic inflammation [30]. This chronic inflammatory response extends beyond the lo- cal infection site, potentially spreading to surrounding tissues and even trigger- ing systemic reactions. At the infection site, the release of numerous pro-inflam- matory factors attracts macrophages and neutrophils. While these cells elimi- nate pathogens, they also release reactive oxygen species (ROS) and reactive ni- trogen species (RNS), causing severe damage to host cells [31]. Such fibrosis is a major cause of anatomical abnormalities like tubal obstruction and cervical stenosis, while also significantly increasing the risk of infertility and ectopic pregnancy. Chronic inflammation further exacerbates the pathological process by promot- ing angiogenesis and altering the microenvironment. Under persistent inflamma- tory conditions, vascular endothelial growth factor (VEGF) levels rise significantly, leading to abnormal blood vessel formation. These neovessels not only supply nu- trients and oxygen for pathogen survival and spread but may also worsen local hemorrhage and tissue destruction due to increased vascular fragility. Notably, Chlamydia trachomatis infection may also trigger systemic immune dysregulation during chronic inflammation, such as elevated systemic IL -1β and IFN-γ levels, thereby affecting other organ functions and potentially correlating with certain autoimmune diseases. 4. Association between Endometriosis and Cervical Ureaplasma and Chlamydia Infections Endometriosis and cervical ureaplasma and chlamydia infections are two com- mon diseases of the female reproductive system. Although they differ in etiology and presentation, recent studies suggest a potential correlation between the two. Chronic inflammation and immune dysregulation triggered by cervical infections may promote the development of endometriosis, while the chronic inflammatory

in endometriosis patients may also increase susceptibility to patho- gen infections. Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 217 Journal of Biosciences and Medicines 4.1. Epidemiological Evidence Supporting Correlation Epidemiological studies indicate significantly elevated rates of Mycoplasma and Chlamydia infections among endometriosis patients, providing preliminary evi- dence for a potential association. A study of infertile women found Chlamydia infection rates exceeding 30% in those with endometriosis, markedly higher than in women without the condition [32]. The prevalence of Ureaplasma infection is also markedly elevated in endometriosis patients, particularly in the context of chronic pelvic inflammatory disease [33]. This suggests that mycoplasma and chlamydia infections may promote the onset and progression of endometriosis through mechanisms such as inducing inflammation or immune dysregulation. Higher detection rates of mycoplasma and chlamydia infections are observed in patients with severe endometriosis. This reflects the role of pathogen infection in sustaining a chronic inflammatory environment and suggests a potentially mu- tually reinforcing vicious cycle between the two. While existing epidemiological data provide important clues, limitations in sample size and inconsistent stand- ards across studies restrict the generalizability of these findings [34]. 4.2. Interactions among Inflammatory Pathways The inflammatory response induced by Mycoplasma and Chlamydia infections is considered a key mechanism linking these pathogens to endometriosis [35]. My- coplasma and Chlamydia infections are typically accompanied by local and sys- temic inflammatory responses, manifested as elevated pro -inflammatory cyto- kines (e.g., IL-6, IL-1β, and TNF-α). These inflammatory mediators are also core pathological factors in endometriosis, supporting the implantation and growth of endometrial cells migrating retrograde into the pelvis by enhancing local angio- genesis and matrix degradation. Studies indicate that Chlamydia infection significantly amplifies local and sys- temic inflammatory responses by activating the NF -κB signaling pathway. This mechanism closely parallels the abnormal inflammatory pathways observed in en- dometriosis patients. This shared inflammatory mechanism may represent a key link in the correlation between the two conditions. Additionally, Ureaplasma in- fection further exacerbates endometriosis by inducing excessive prostaglandin E2 (PGE2) secretion, thereby promoting vascul arization and dissemination of ec- topic endometrial tissue [36] [37]. Chronic inflammation not only supports the implantation and growth of ec- topic endometrial tissue but also impairs the immune system ’s ability to clear it. Immune cells activated by the local inflammatory response— such as macrophages and neutrophils— release large amounts of reactive oxygen species and enzymatic substances while phagocytosing pathogens, causing damage to surrounding tis- sues. This chronic inflammatory environment may provide a crucial foundation for the interaction between the two diseases. 4.3. Impact of Immunomodulation Both endometriosis and cervical Mycoplasma/Chlamydia infections are closely Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 218 Journal of Biosciences and Medicines associated with immune dysregulation. Studies indicate that the immune systems of endometriosis patients exhibit significant immune evasion phenomena, such as reduced natural killer (NK) cell activity and impaired macrophage function. This immune dysfunction facilitates the implantation and survival of endometrial tis- sue ascending into the pelvic cavity [35]. Mycoplasma and Chlamydia infections further weaken host immune defenses through their immune evasion mechanisms (e.g., antigenic variation, suppression of host MHC molecule expression), establishing a chronic infection state. Further- more, infection-induced disruption of the mucosal barrier and abnormal immune regulation may provide pathways for ectopic endometrial migration. For example, Chlamydia infection significantly activates matrix metalloproteinases (e.g., MMP- 2, MMP-9), promoting extracellular matri x degradation and thereby enhancing the invasiveness of ectopic endometrial tissue. The interaction of these mecha- nisms may play a key role in the mutual promotion of both diseases. 4.4. Role of Microbiome and Pelvic Environment Epidemiological evidence first suggests a “infection-first, ectopic-later” temporal association between lower genital tract pathogen infections and endometriosis (EMs): A cohort study in Taiwan Region covering 79,518 cases of cervical/vagini- tis patients showed that lower genital tract infections approximately doubled the risk of subsequent EMs (adjusted HR = 2.01, 95% CI 1.91 - 2.12). This finding establishes a population-based foundation for the “pathogen-microbiome-endo- metriosis” triadic linkage [38]. At the microbial level, a 2024 systematic review and meta-analysis published in PLOS One (8 population studies, n = 1063) indicated that compared to a normal microbiome dominated by lactobacilli, vaginal dysbiosis (BV/moderate BV) was positively correlated with EMs (pooled OR = 1.17), while Lactobacillus-dominant microbiomes may confer protective effects [39]. Metagenomic sequencing further revealed dysbiosis patterns. Studies have shown that EMs patients exhibit signifi- cant loss of Lactobacillus iners in the vagina, accompanied by enrichment of op- portunistic pathogens such as Anaerococcus, Prevotella, Porphyro monas, and Ureaplasma urealyticum, along with increased overall α-diversity. This suggests that after disruption of the lactobacilli-mediated low pH barrier, anaerobic bacte- ria and mycoplasmas gain a survival advantage [40]. This microbial “displace- ment” not only elevates local pH and weakens the mucosal barrier but also ampli- fies pro-inflammatory factors like IL -6 and TNF - α through the Toll -like recep- tor/NF-κB pathway, providing an inflammatory backdrop for ectopic endometrial cell adhesion, angiogenesis, and matrix remodeling. The causality of pathogen - microbiome interactions in lesion progression was further validated in animal studies: In a mouse endometrioma (EMs) model, vaginal broad-spectrum antibi- otic pretreatment or vaginal microbiota transplantation (VMT) from healthy do- nors significantly reduced lesion volume, decreased Ki -67 expression, and low- ered IL-1 β/IL-6/TNF-α levels in peritoneal fluid. This effect was closely associated Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 219 Journal of Biosciences and Medicines with NF-κB signaling inhibition. These findings suggest that restoring a Lactoba- cillus-dominant acidic ecosystem or inhibiting NF -κB-mediated inflammatory pathways may represent promising microbiome- based therapeutic strategies for managing EMs. In summary, vaginal Lactobacillus depletion and pH elevation induced by path- ogens such as Mycoplasma and Chlamydia not only compromise the mucosal bar- rier but also trigger chronic inflammation and angiogenesis signals, creating a “soft landing” environment conducive to endometrial implantation and expan- sion. Future research may explore novel approaches for preventing and treating EMs through targeted probiotics, vaginal microbiome therapy (VMT), and com- bined microbiome-immunomodulatory interventions targeting NF- κB. 4.5. Increased Susceptibility to Cervical Mycoplasma and Chlamydia in Endometriosis Patients The chronic inflammation and immune dysregulation in endometriosis patients may conversely increase their susceptibility to pathogen infections. On one hand, the pro-inflammatory environment of ectopic lesions further activates local in- flammatory pathways, exacerbating damage to the cervical epithelial barrier [7] [41]; On the other hand, chronic inflammation may compromise local immune barriers, rendering the cervix more susceptible to Mycoplasma and Chlamydia infections [42] [43]. This susceptibility not only increases the risk of infection oc- currence but may also lead to more severe infection manifestations and treatment challenges. Furthermore, studies reveal significantly reduced diversity of the reproductive tract microbiota and increased proportions of opportunistic pathogens in endo- metriosis patients, suggesting that susceptibility to infection may be influenced by microbiome imbalance. For instance, reduced lactobacilli may weaken local anti- microbial activity, while proliferation of opportunistic pathogens may intensify inflammatory responses [44]. This complex interplay between the microbiota and the inflammatory environment offers a new interpretive dimension for the asso- ciation between endometriosis and cervical infection. 5. Discussions This review analyzes the potential association between endometriosis and cervical Mycoplasma/Chlamydia infections, examining their mutual influences on inflam- mation, immunity, and the microbiome, and subsequently explores targeted pre- vention and treatment strategies. Existing research suggests that chronic inflam- mation and immune dysregulation induced by cervical infections may promote the onset and progression of endometriosis [45]-[47]. Conversely, the local or sys- temic inflammatory state in endometriosis patients may increase susceptibility to pathogens. However, studies on the specific mechanisms underlying this relation- ship require further investigation. Studies confirm that high levels of pro -inflammatory cytokines (e.g., TNF -α, Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 220 Journal of Biosciences and Medicines IL-6, IL-1β) induced by Mycoplasma and Chlamydia infections also show a sig- nificant upward trend in endometriosis patients, suggesting mutual promotion through shared inflammatory pathways [48] [49]. Infection-induced disruption of the mucosal barrier and dysbiosis may also provide a “fertile ground” for the implantation of ectopic endometrial cells within the pelvis, further intensifying the pathological process of endometriosis. While numerous in vitro and animal model studies have partially validated that infection exacerbates chronic pelvic inflammation, large-scale population cohort data remain lacking to clarify the true extent of infection’s impact on endometriosis pathogenesis. Our research reveals that endometriosis remains highly challenging to manage clinically. Current interventions often focus on controlling symptoms and pro- gression of individual conditions— such as hormone regulation and surgical ap- proaches for endometriosis, or antibiotic treatment for mycoplasma and chla- mydia infections. However, if significant interaction between these two factors exists, treatment strategies must urgently consider their potential mutual influ- ence. Existing literature indicates that concurrently controlling inflammation and correcting microecological imbalances in infected patients may help reduce chronic pelvic inflammation levels, thereby indirectly decreasing ectopic lesion implanta- tion and spread [50]. Combining anti-infective therapy with interventions such as immunomodulation or probiotic supplementation may break the “infection -in- flammation-ectopic” cycle, enhancing clinical efficacy and reducing recurrence [51]. However, due to the lack of unified screening criteria and large- scale pro- spective studies, the specific indications and efficacy evaluation of combined ther- apy remain to be further established. The rapid advancement of precision medicine offers new approaches to address these challenges. Through multi-omics technologies such as genomics, transcriptom- ics, and microbiomics, we can analyze individual differences between endometri- osis and cervical infections at the molecular level, identify high- risk populations, and implement personalized interventions targeting their immune, inflammatory, or microbiome characteristics. For instance, patients with specific inflammatory gene variants or dysbiotic micr obiomes may benefit more from targeted inflam- matory inhibitor therapies or microbiome restoration strategies. Furthermore, de- veloping long -acting anti -inflammatory drugs and novel immunomodulators could significantly enhance treatment efficacy for recurrent or refractory cases. Although existing studies preliminarily reveal potential links between endome- triosis and cervical Mycoplasma or Chlamydia infections, larger -scale epidemio- logical investigations and high -quality randomized controlled trials are still needed to clarify the causal relationship between the two and the benefits of in- tervention. The application of multimodal studies (e.g., integrating imaging, mo- lecular diagnostics, and immunological assessments) can further elucidate the in- tersection of these two diseases at the inflammation -immunity-microenviron- ment level, providing robust support for early screening and comprehensive pre- vention strategies. In the future, establishing a unified combined screening pro- Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 221 Journal of Biosciences and Medicines cess in clinical practice and exploring a comprehensive management model cen- tered on “anti-infection-inflammation control-microecological restoration” may significantly improve patient symptoms and long-term reproductive outcomes. In summary, endometriosis and cervical Mycoplasma/Chlamydia infections may interact through shared mechanisms involving inflammatory pathways, im- mune dysregulation, and microecological imbalance. Clarifying their specific as- sociations and implementing comb ined interventions not only deepens our un- derstanding of endometriosis pathogenesis but also holds promise for delivering more precise and efficient diagnostic and therapeutic pathways for patients. With the integration of more clinical evidence and multid isciplinary technologies, a more comprehensive diagnostic and treatment system may emerge in the field of female reproductive health, offering new opportunities and directions for the pre- vention and management of such diseases. The rapid advancement of precision medicine offers hope for the integrated management of endometriosis and cervical infections. Genomics and multi-omics technologies enable deeper exploration of disease heterogeneity across patients, facilitating the identification of high-risk populations and the delivery of person- alized prevention and treatment strategies. For instance, patients with specific in- flammatory gene mutations or dysbiotic microbiomes may benefit more from tar- geted inflammatory inhibitor or micr obiota restoration strategies than conven- tional therapies [9] [52] [53]. Furthermore, developing long -acting anti-inflam- matory drugs and immunomodulators for recurrent or refractory cases could sig- nificantly enhance treatment efficacy. Conflicts of Interest The authors declare no conflicts of interest regarding the publication of this paper.

[1] Giudice, L.C. and Kao, L.C. (2004) Endometriosis. The Lancet, 364, 1789-1799. https://doi.org/10.1016/s0140-6736(04)17403-5 [2] Guo, S.-W. (2009) Epigenetics of Endometriosis. Molecular Human Reproduction , 15, 587-607. https://doi.org/10.1093/molehr/gap064 [3] Burney, R.O. and Giudice, L.C. (2012) Pathogenesis and Pathophysiology of Endo- metriosis. Fertility and Sterility, 98, 511-519. https://doi.org/10.1016/j.fertnstert.2012.06.029 [4] Somer, A., Salman, N., Yalçın, I. and Ağaçfidan, A. (2006) Role of Mycoplasma Pneu- moniae and Chlamydia Pneumoniae in Children with Community -Acquired Pneu- monia in Istanbul, Turkey. Journal of Tropical Pediatrics, 52, 173-178. https://doi.org/10.1093/tropej/fml017 [5] Wang, Z., Guo, S., Xie, Y., Tong, Y., Qi, W. and Wang, Z. (2024) Endometrial Ex- pression of ERRβ and ERRγ: Prognostic Significance and Clinical Correlations in Se- vere Endometriosis. Frontiers in Endocrinology, 15, Article ID: 1489097. https://doi.org/10.3389/fendo.2024.1489097 [6] De Andrade, V.T., Nácul, A.P., Dos Santos, B.R., Lecke, S.B., Spritzer, P.M. and Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 222 Journal of Biosciences and Medicines Morsch, D.M. (2017) Circulating and Peritoneal Fluid Interleukin-6 Levels and Gene Expression in Pelvic Endometriosis. Experimental and Therapeutic Medicine , 14, 2317-2322. https://doi.org/10.3892/etm.2017.4794 [7] Wang, X.M., Ma, Z.Y. and Song, N. (2018) Inflammatory Cytokines IL-6, IL-10, IL- 13, TNF-Alpha and Peritoneal Fluid Flora Were Associated with Infertility in Patients with Endometriosis. European Review for Medical and Pharmacological Sciences, 22, 2513-2518. [8] Yan, J., Liu, C., Zhao, H., Wang, C., Yao, H., Lu, Q., et al. (2020) A Cross-Sectional Study on the Correlation between Cytokines in a Pelvic Environment and Tubal Fac- tor Infertility. BMC Pregnancy and Childbirth, 20, Article No. 644. https://doi.org/10.1186/s12884-020-03322-y [9] Campos, G.B., Marques, L.M., Rezende, I.S., Barbosa, M.S., Abrão, M.S. and Timenetsky, J. (2018) Mycoplasma Genitalium Can Modulate the Local Immune Re- sponse in Patients with Endometriosis. Fertility and Sterility, 109, 549-560.e4. https://doi.org/10.1016/j.fertnstert.2017.11.009 [10] Hillis, S.D., Owens, L.M., Marchbanks, P.A., Amsterdam, L.E. and Mac Kenzie, W.R. (1997) Recurrent Chlamydial Infections Increase the Risks of Hospitalization for Ec- topic Pregnancy and Pelvic Inflammatory Disease. American Journal of Obstetrics and Gynecology, 176, 103-107. https://doi.org/10.1016/s0002-9378(97)80020-8 [11] Taylor-Robinson, D. (1998) The Role of Ureaplasma Urealyticum . International Journal of STD & AIDS, 9, 123-124. [12] Brook, I. and Gober, A.E. (2005) Antimicrobial Resistance in the Nasopharyngeal Flora of Children with Acute Otitis Media and Otitis Media Recurring after Amoxi- cillin Therapy. Journal of Medical Microbiology, 54, 83-85. https://doi.org/10.1099/jmm.0.45819-0 [13] Hellstrom, W.J.G., Schachter, J., Sweet, R.L. and Dale McClure, R. (1987) Is There a Role for Chlamydia Trachomatis and Genital Mycoplasma in Male Infertility? Fertil- ity and Sterility, 48, 337-339. https://doi.org/10.1016/s0015-0282(16)59370-4 [14] Imudia, A.N., Detti, L., Puscheck, E.E., Yelian, F.D. and Diamond, M.P. (2008) The Prevalence of Ureaplasma Urealyticum, Mycoplasma Hominis, Chlamydia Tracho- matis and Neisseria Gonorrhoeae Infections, and the Rubella Status of Patients Un- dergoing an Initial Infertility Evaluation. Journal of Assisted Reproduction and Ge- netics, 25, 43-46. https://doi.org/10.1007/s10815-007-9192-z [15] Moini, A., Riazi, K., Amid, V., Ashrafi, M., Tehraninejad, E., Madani, T., et al. (2005) Endometriosis May Contribute to Oocyte Retrieval -Induced Pelvic Inflammatory Disease: Report of Eight Cases. Journal of Assisted Reproduction and Genetics , 22, 307-309. https://doi.org/10.1007/s10815-005-6003-2 [16] Matysiak-Klose, D., Mankertz, A. and Holzmann, H. (2024) The Epidemiology and Diagnosis of Measles — Special Aspects Relating to Low Incidence. Deutsches Ärz- teblatt international, 121, 875-881. https://doi.org/10.3238/arztebl.m2024.0211 [17] Curty, G., de Carvalho, P.S. and Soares, M.A. (2019) The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepi- thelial Neoplasia and Invasive Cervical Cancer. International Journal of Molecular Sciences, 21, Article 222. https://doi.org/10.3390/ijms21010222 [18] Lehtinen, M., Luukkaala, T., Wallin, K., Paavonen, J., Thoresen, S., Dillner, J., et al. (2001) Human Papillomavirus Infection, Risk for Subsequent Development of Cer- vical Neoplasia and Associated Population Attributable Fraction. Journal of Clinical Virology, 22, 117-124. https://doi.org/10.1016/s1386-6532(01)00172-x [19] Ravel, J., Gajer, P., Abdo, Z., Schneider, G.M., Koenig, S.S.K., McCulle, S.L., et al. Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 223 Journal of Biosciences and Medicines (2011) Vaginal Microbiome of Reproductive -Age Women. Proceedings of the Na- tional Academy of Sciences, 108, 4680-4687. https://doi.org/10.1073/pnas.1002611107 [20] Renz, K.G., Cooke, J., Clarke, N., Cheetham, B.F., Hussain, Z., Fakhrul Islam, A.F.M., et al. (2012) Pathotyping of Australian Isolates of Marek’s Disease Virus and Associ- ation of Pathogenicity with Meq Gene Polymorphism. Avian Pathology, 41, 161-176. https://doi.org/10.1080/03079457.2012.656077 [21] McCormack, W.M. (1994) Pelvic Inflammatory Disease. New England Journal of Medicine, 330, 115-119. https://doi.org/10.1056/nejm199401133300207 [22] Brunham, R.C., Martin, D.H., Kuo, C.C., Wang, S.P., Stevens, C.E., Hubbard, T., et al. (1981) Cellular Immune Response during Uncomplicated Genital Infection with Chlamydia Trachomatis in Humans. Infection and Immunity, 34, 98-104. https://doi.org/10.1128/iai.34.1.98-104.1981 [23] Beatty, W.L., Morrison, R.P. and Byrne, G.I. (1994) Persistent Chlamydiae: From Cell Culture to a Paradigm for Chlamydial Pathogenesis. Microbiological Reviews , 58, 686-699. https://doi.org/10.1128/mr.58.4.686-699.1994 [24] Zhang, Q., Xing, X., Liu, S., Xie, X., Liu, X., Qian, F., et al. (2019) Intramural Ectopic Pregnancy Following Pelvic Adhesion: Case Report and Literature Review. Archives of Gynecology and Obstetrics, 300, 1507-1520. https://doi.org/10.1007/s00404-019-05379-3 [25] Pi, R., Liu, Y., Zhao, X., Liu, P. and Qi, X. (2020) Tubal Infertility and Pelvic Adhesion Increase Risk of Heterotopic Pregnancy after in Vitro Fertilization: A Retrospective Study. Medicine, 99, e23250. https://doi.org/10.1097/md.0000000000023250 [26] Oliveira Souza Lima, S.R., Kanemitsu, K., Rashid, M., Patel, V.K. and Ali, M. (2024) Long-term Efficacy and Safety of Adhesion Prevention Agents in Abdominal and Pel- vic Surgeries: A Systematic Review. Cureus, 16, e71280. https://doi.org/10.7759/cureus.71280 [27] Machado, A.C.S., Bandea, C.I., Alves, M.F.C., Joseph, K., Igietseme, J., Miranda, A.E., et al. (2011) Distribution of Chlamydia Trachomatis Genovars among Youths and Adults in Brazil. Journal of Medical Microbiology, 60, 472-476. https://doi.org/10.1099/jmm.0.026476-0 [28] Sehnem, L., Bodanese, L.C., Repetto, G. and Staub, H.L. (2010) Iga Antibodies to chlamydia Trachomatis and Metabolic Syndrome. Microbiology and Immunology , 54, 747-749. https://doi.org/10.1111/j.1348-0421.2010.00281.x [29] Lorimer, K. and Hart, G.J. (2010) Knowledge of Chlamydia Trachomatis among Men and Women Approached to Participate in Community -Based Screening, Scotland, Uk. BMC Public Health, 10, Article No. 794. https://doi.org/10.1186/1471-2458-10-794 [30] Townsend, L.C., Stahlman, S.L., Escobar, J.D., Osuna, A.B., Casey, T.M., Winkler, E.L., et al. (2024) Positivity and Follow -Up Testing of Chlamydia Trachomatis and Neisseria Gonorrhoeae Infections in Universally Screened Female Basic Military Trainees. Sexually Transmitted Diseases, 52, 176-180. https://doi.org/10.1097/olq.0000000000002099 [31] Shen, L., Diggs, C., Ferdous, S., et al. (2024) The SWIB Domain -Containing DNA Topoisomerase I of Chlamydia Trachomatis Mediates DNA Relaxation. bioRxiv. [32] Khan, K.N., Fujishita, A., Kitajima, M., Ishimaru, T., Ogawa, K., Koshiba, A., et al. (2021) Decreased Occurrence of Endometriosis in Women with Chlamydia tracho- matis Infection. American Journal of Reproductive Immunology, 86, e13498. https://doi.org/10.1111/aji.13498 Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 224 Journal of Biosciences and Medicines [33] Gazvani, R., Coyne, L., Anttila, T., Saikku, P., Paavonen, J. and Templeton, A. (2011) Antibodies to Chlamydia trachomatisin Serum and Peritoneal Fluid of Women with Endometriosis. Human Fertility, 14, 64-67. https://doi.org/10.3109/14647273.2010.548846 [34] Oppelt, P., Renner, S.P., Strick, R., Valletta, D., Mehlhorn, G., Fasching, P.A., et al. (2010) Correlation of High -Risk Human Papilloma Viruses but Not of Herpes Vi- ruses or Chlamydia Trachomatis with Endometriosis Lesions. Fertility and Sterility, 93, 1778-1786. https://doi.org/10.1016/j.fertnstert.2008.12.061 [35] Ross, P. (2021) Retraction: Ginsenoside Rf Alleviates Dysmenorrhea and Inflamma- tion through the BDNF-TrkB-CREB Pathway in a Rat Model of Endometriosis. Food & Function, 12, 5187. https://doi.org/10.1039/d1fo90040d [36] Wu, M. and Zhang, Y. (2021) MiR -182 Inhibits Proliferation, Migration, Invasion and Inflammation of Endometrial Stromal Cells through Deactivation of NF-κB Sig- naling Pathway in Endometriosis. Molecular and Cellular Biochemistry , 476, 1575- 1588. https://doi.org/10.1007/s11010-020-03986-2 [37] Sekulovski, N., Whorton, A.E., Tanaka, T., Hirota, Y., Shi, M., MacLean, J.A., et al. (2020) Niclosamide Suppresses Macrophage-Induced Inflammation in Endometrio- sis. Biology of Reproduction, 102, 1011-1019. https://doi.org/10.1093/biolre/ioaa010 [38] MacSharry, J., Kovács, Z., Xie, Y., Adamczyk, B., Walsh, C., Reidy, F., et al. (2024) Endometriosis Specific Vaginal Microbiota Links to Urine and Serum N -Glycome. Scientific Reports, 14, Article No. 25372. https://doi.org/10.1038/s41598-024-76125-2 [39] Qing, X., Xie, M., Liu, P., Feng, O., Leng, H., Guo, H., et al. (2024) Correlation be- tween Dysbiosis of Vaginal Microecology and Endometriosis: A Systematic Review and Meta-Analysis. PLOS ONE, 19, e0306780. https://doi.org/10.1371/journal.pone.0306780 [40] Lu, F., Wei, J., Zhong, Y., Feng, Y., Ma, B., Xiong, Y., et al. (2022) Antibiotic Therapy and Vaginal Microbiota Transplantation Reduce Endometriosis Disease Progression in Female Mice via NF -κB Signaling Pathway. Frontiers in Medicine, 9, Article ID: 831115. https://doi.org/10.3389/fmed.2022.831115 [41] Fan, Y., Chen, H., Chen, W., Liu, Y., Fu, Y. and Wang, L. (2018) Expression of In- flammatory Cytokines in Serum and Peritoneal Fluid from Patients with Different Stages of Endometriosis. Gynecological Endocrinology, 34, 507-512. https://doi.org/10.1080/09513590.2017.1409717 [42] Drugan, T., Malutan, A., Ciortea, R., Mocan-Hognogi, R., Bucuri, C., Rada, M., et al. (2015) Serum Anti-Inflammatory Cytokines for the Evaluation of Inflammatory Sta- tus in Endometriosis. Journal of Research in Medical Sciences, 20, 668-674. https://doi.org/10.4103/1735-1995.166215 [43] Wu, M. and Ho, H. (2003) The Role of Cytokines in Endometriosis. American Jour- nal of Reproductive Immunology, 49, 285-296. https://doi.org/10.1034/j.1600-0897.2003.01207.x [44] Silva, B.N., Fernandes, N., Carvalho, L., et al. (2023) Lactic Acid Bacteria from Arti- sanal Raw Goat Milk Cheeses: Technological Properties and Antimicrobial Potential. Italian Journal of Food Safety, 12, Article 11559. [45] Grande, G., Vincenzoni, F., Milardi, D., Pompa, G., Ricciardi, D., Fruscella, E., et al. (2017) Cervical Mucus Proteome in Endometriosis. Clinical Proteomics, 14, Article No. 7. https://doi.org/10.1186/s12014-017-9142-4 Z. D. Wei, C. J. Yi DOI: 10.4236/jbm.2025.1311015 225 Journal of Biosciences and Medicines [46] Lin, Y., Chen, Y., Chang, H., Au, H., Tzeng, C. and Huang, Y. (2018) Chronic Niche Inflammation in Endometriosis -Associated Infertility: Current Understanding and Future Therapeutic Strategies. International Journal of Molecular Sciences, 19, Arti- cle 2385. https://doi.org/10.3390/ijms19082385 [47] Peipert, J.F., Ness, R.B., Blume, J., Soper, D.E., Holley, R., Randall, H., et al. (2001) Clinical Predictors of Endometritis in Women with Symptoms and Signs of Pelvic Inflammatory Disease. American Journal of Obstetrics and Gynecology , 184, 856- 864. https://doi.org/10.1067/mob.2001.113847 [48] Zhou, W., Yang, H., Shao, J., Mei, J., Chang, K., Zhu, R., et al. (2019) Anti-Inflamma- tory Cytokines in Endometriosis. Cellular and Molecular Life Sciences , 76, 2111- 2132. https://doi.org/10.1007/s00018-019-03056-x [49] Malutan, A.M., Drugan, T., Costin, N., Ciortea, R., Bucuri, C., Rada, M.P., et al. (2015) Clinical Immunology Pro-Inflammatory Cytokines for Evaluation of Inflam- matory Status in Endometriosis. Central European Journal of Immunology , 1, 96- 102. https://doi.org/10.5114/ceji.2015.50840 [50] Liang, Y., Zhao, C., Wen, Y., Sheng, D., Wei, T., Hu, T., et al. (2024) Modulation of Local Immunity by the Vaginal Microbiome Is Associated with Triggering Spontane- ous Preterm Birth. Frontiers in Immunology, 15, Article ID: 1481611. https://doi.org/10.3389/fimmu.2024.1481611 [51] Li, J., Zhu, Y., Mi, J., Zhao, Y., Holyoak, G.R., Yi, Z., et al. (2022) Endometrial and Vaginal Microbiome in Donkeys with and without Clinical Endometritis. Frontiers in Microbiology, 13, Article ID: 884574. https://doi.org/10.3389/fmicb.2022.884574 [52] Dolmans, M. and Donnez, J. (2022) Emerging Drug Targets for Endometriosis. Bio- molecules, 12, Article 1654. https://doi.org/10.3390/biom12111654 [53] Guo, C. and Zhang, C. (2024) Role of the Gut Microbiota in the Pathogenesis of En- dometriosis: A Review. Frontiers in Microbiology, 15, Article ID: 1363455. https://doi.org/10.3389/fmicb.2024.1363455